The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review.
The management of keloids and hypertrophic scars continues to challenge health-care providers. Though both forms of pathologic scarring are distinct entities at the macro and microscopic level, their etiologies and treatment are often similar. Potential treatment approaches are progressing, and combinations of treatment options have been proposed in the literature with promising outcomes. The treatment evolution has reached a level where molecular therapeutic modalities are being investigated. Currently, no gold standard treatment exists. Overall success rates and patient satisfaction seem to be slowly climbing, but additional investigational studies must continue to be performed. Several studies have investigated antineoplastic agents, and there seems to be a marked improvement in rates of recurrence, patient satisfaction, and overall quality of scar when these agents are used. Intralesional injection and/or wound irrigation with interferon-a2b, interferon-g, mitomycin-C, bleomycin, or 5-fluorouracil seems to have a positive effect on the reduction of pathologic scars. There is mounting evidence that these drugs used alone or in combination therapy, have the potential to be an integral part of the treatment paradigm for hypertrophic scars and keloids.
Shridharani
Sachin M
SM
Division of Plastic, Reconstructive and Maxillofacial Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Magarakis
Michael
M
Manson
Paul N
PN
Singh
Navin K
NK
Basdag
Basak
B
Rosson
Gedge D
GD
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002921:Cicatrix / Q000188:drug therapy* / Q000473:pathology*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D006984:Hypertrophy / Q000188:drug therapy / Q000473:pathology; D016898:Interferon-alpha / Q000627:therapeutic use; D007627:Keloid / Q000188:drug therapy* / Q000473:pathology*; D016685:Mitomycin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D001761:Bleomycin; D016685:Mitomycin; D005472:Fluorouracil